Clinical Trial

Veneclax, Chidaniline Combined With Azacitidine Followed by Decitabine + MAG Regimen in the Treatment of Elderly Untreated AML

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 20, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
A multicenter, prospective, single-arm clinical study of veneclax, chidaniline combined with azacitidine (VCA) followed by decitabine + MAG regimen (D-MAG) in the treatment of elderly untreated acute myeloid leukemia (AML)
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-02-11.
Trial Details
NCT Number NCT06827899
Lead Sponsor The First Affiliated Hospital of Xiamen University
Collaborators: Fujian Provincial Hospital, Fujian Cancer Hospital, Zhangzhou Affiliated Hospital of Fujian Medical University, Jieyang People's Hospital, Huizhou Municipal Central Hospital
Conditions Acute Myeloid Leukemia
Enrollment 66 participants
Start Date 2022-07-01
Primary Completion 2026-06-30 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-02-20